Session Details

Workshop 8 - CAR-T-Racing: The Pro Circuit + Future Prospects
Sunday, September 15, 2019 10:45 AM - 12:15 PM 
Plenary Hall
Chimeric Antigen Receptor (CAR) redirection of T cell specificity ex vivo and reinfusion of CAR T cells to patients with relapsed or refractory advanced cancers has demonstrated remarkable clinical responses, and the international regulatory approval of two products for patients with pediatric and young adult acute lymphoid leukemia, and with diffuse large B cell lymphoma.  Outstanding issues with this therapy include identifying and overcoming mechanisms of resistance, expanding the indications outside of CD19+ malignancies into myeloid malignancies, and manufacturing improvements to gene delivery and control.


Bruce Levine, PhD, University of Pennsylvania, USA


Advancing CAR T cell Product Development for B-ALL to Overcome Resistance
Rebecca Gardner, MD, Seattle Children’s Hospital, USA
Learning objectives:
•      To be able to describe the common mechanisms of resistance to CD19 CAR T cells in B-ALL
•      To be able to understand how products can be specifically engineered to overcome resistance and hopefully lead to more sustained remissions
•      To be able to identify therapeutic products that can be administered in conjunction with CAR T cells to enhance the potency

New Frontiers in Gene Modification and Genetic Engineering of CAR T cells
Krishanu Saha, PhD University of Wisconsin-Madison, USA
Learning objectives:
•      Understand the viral and nonviral methods used to genetically modify blood products during the manufacturing of autologous and allogenic CAR T cells.
•      Deepen knowledge about opportunities to integrate synthetic biology into CAR T cell products.
•      Elucidate bottlenecks in moving novel genetically-engineered CAR T cell products to first-in-man trails.

CART cells for myeloid malignancies
Saar Gill, MD, PhD, Perelman School of Medicine, University of Pennsylvania, USA
Learning objectives:
•      To understand the potential target antigens in myeloid malignancies
•      To describe the clinical outcomes of CAR T cells in patients with acute myeloid leukemia
•      To identify the unique challenges facing CART cell therapy of myeloid malignancies

Bruce Levine PhD
Barbara and Edward Netter Professor in Cancer Gene Therapy
University of Pennsylvania

Rebecca Gardner MD
Seattle Children's Research Institute

Saar Gill MD, PhD
Assistant Professor of Medicine
Perelman School of Medicine, University of Pennsylvania

Krishanu Saha PhD